$280 Million Boost for Disease Genomics

The genomics arm of the National Institutes of Health has pledged a total of $280 million for research into the genetic bases of disease.

Written byCatherine Offord
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

NIH Building 1WIKIMEDIA, NATIONAL CANCER INSTITUTEThe National Human Genome Research Institute (NHGRI) announced in a press release last week (January 14) that it will provide more than $240 million over the next four years to fund research into the genomic variation underlying common diseases.

“The time is right for a very large-scale human genome sequencing program” in order to understand, “the genetic and environmental causes of common diseases,” NHGRI Director Eric Green told reporters (via STAT News). “The kind of information that can come out of this is overwhelmingly medically important.”

To spearhead the project, NHGRI has launched the Centers for Common Disease Genomics (CCDG), which will focus on diseases including diabetes, autism, and heart disease. Researchers at four funded centers associated with universities and colleges across the U.S. will sequence tens of thousands of genomes from individuals with and without the diseases in order to identify underlying genomic causes and correlations. The National Heart, Lung, and Blood Institute will provide an additional $20 million for the CCDG centers, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies